

offene Studien Onkologie USB

Ansprechperson: mana.farsad@usb.ch

Indikation	Name	Studienbeschreibung	PI/CRC
Hirntumore			
Hals-Nasen-Ohren Tumore			
Erstlinientherapie	MK3475-048	A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	SR/SH
Lungenkrebs			
Kleinzeller, limitierte Erkrankung	SAKK 15/12	Frühzeitige prophylaktische Ganzhirnbestrahlung bei LD	AP/IS
NSCLC St. IIIA neo- & adjuv.	SAKK 16/14	Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC).	SR/MF
NSCLC Stage IB (T≥4cm)–II–IIIA adjuv.	PEARLS	A randomized, phase 3 trial with pembrolizumab(MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	SR/MF
NSCLC Erstlinientherapie	CA209 227	Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent NSCLC	SR/MF
NSCLC Erstlinientherapie	MSD Keynote 042	Pembrolizumab vs. Carboplatin + Alimta/Taxol 1:1 randomisiert bei PD-L pos. Patienten	AZ/MF
NSCLC, EGFR Wildtyp, later line	CINC280A2201	A Phase II, Multicenter, Four-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease	SR/MF

offene Studien Onkologie USB

Ansprechperson: mana.farsad@usb.ch

NSCLC	Nouscom	An observational study in NSCLC patients to characterize changes of the mutational landscape and of the immune cell activation status after anti-PD-1 antibody treatment	AW/MF
Brustkrebs			
Metast. Brust- oder Prostatakarzinom mit Knochenmetastasen	SAKK 96/12	Therapie mit Denosumab (XGEVA) zur Prävention von skelettbez. Komplikation bei Knochenmetastasen	SR/SH
adjuvant	IBCSG POSITIVE	Beurteilung der Schwangerschaftsergebnisse und der Unbedenklichkeit eines Unterbruchs der Hormontherapie bei jungen Frauen mit einem hormonrezeptorpositiver Mammakarzinom, die schwanger werden möchten	MV/BB
adjuvant	PALLAS	PALbociclib CoLLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer	MV/BB
Brustkrebs beim Mann	EORTC 10085	Klinische und biologische Charakterisierung; keine Therapieempfehlung	CR/BB
triple-neg, Erstlinientherapie	WO2952 IMpassion	A phase III, multicenter, randomized, placebo-controlled study of atezolizumab (anti-PD-L1 antibody) in combination with nfor patients with previously untreated metastatic triple-negative breast cancer	CR/BB
triple-neg, Erstlinientherapie	SAKK 24/14	Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer - A multicenter single arm phase II trial	CR/BB
HER2-neg, Erstlinientherapie	SAKK 25/14	Eribulin as 1st line treatment in elderly patients (≥ 70 years) with advanced breast cancer	CR/BB

offene Studien Onkologie USB

Ansprechperson: mana.farsad@usb.ch

Metastasierte, vorbehandelte Erkrankung: Her2 negativ + HormonRezeptor positiv oder triple-neg + Androgen Rezeptor positiv	SAKK 21/12	A Phase I and stratified, multicenter Phase II trial of transdermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer	MV/BB
Gastrointestinale Tumoren			
Magenkrebs, metastasiert, Erstlinientherapie	MK-3475-062	A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	VH/SH
Dickdarmkrebs, adjuvant	SAKK 41/13	Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial	AW/SH
Dickdarmkrebs, metastasiert, Erstlinientherapie	SAKK 41/14 ACTIVE	Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled phase III trial	VH/SH
Enddarmkrebs, lokal fortgeschritten	Prospect	A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	AW/SH
Leberkrebs, inoperabel, Erstlinientherapie	CA209-459	A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced HCC	VH/US
LYMPHOME			
Hodgkin Lymphom, mittlere Stadien	HD 17	Therapiestratifizierung mittels FDG-PET	FK/MF
Follikuläres Lymphom, wenig Tumorlast	B3281006	randomized, double-blind study of PF05280586 vs. Rituximab for 1st line treatment of patients with CD20+	FK/BB

offene Studien Onkologie USB

Ansprechperson: mana.farsad@usb.ch

Folikuläres Lymphom, Erstlinientherapie für fortgeschrittene Erkrankung	SAKK 35/14	Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.	FK
UROGENITAL-Tumoren			
Prostatakrebs, hormonsensibel	STAMPEDE	Hormonentzug (HE) vs HE+Zometa vs HE+ Taxotere vs HE+Zometa+Taxotere vs HE+Abiraterone	Urologie
Prostatakrebs, kastrationsresistent	SAKK 08/14	Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalutamide vs. Enzalutamide alone (IMPROVE TRIAL)	SR/SH
Prostatakrebs, fortgeschritten, vorbehandelt mit Chemotherapie	MK 3475 199	Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy	FS/
Prostatakrebs, kastrationsresistent, vorbehandelt mit Abiraterone	Abi-Re	Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients with Metastatic Castration-Resistant Prostate Cancer and prior Response to AA	SR/
Blasenkrebs, operiert (adjuvant)	CA209 274	A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma	FS/AB
Metast. Brust- oder Prostatakarzinom mit Knochenmetastasen	SAKK 96/12	Therapie mit Denosumab (XGEVA) zur Prävention von skelettbez. Komplikationen bei Knochenmetastasen	SR/SH
Hodentumore: Seminom	SAKK 01/10	Carboplatin (AUC 7) gefolgt von "involved node" Radiotherapie	AP/IS
Hautkrebs			
Melanom, fortgeschritten, Erstlinientherapie	CA209 401	Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma	AW/BB
Phase I Studien			
Lebermetastasen bei Darmkrebs	AvidinOX, ST2211	Intra-lesionally injected AvidinOX, followed by systemic IV administration of escalating doses of (177Lu)DOTA-biotin in patients with liver metastases from CRC	AW/MF